Kaposis Sarcoma Pipeline Insight
DelveInsight’s, “Kaposi’s Sarcoma – Pipeline Insight, 2021,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kaposi’s Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Kaposi’s Sarcoma Understanding
Kaposi’s Sarcoma: Overview
Kaposi sarcoma, also called idiopathic multiple pigmented hemorrhagic sarcoma, rare and usually lethal cancer of the tissues beneath the surface of the skin or of the mucous membranes. The disease can spread to other organs, including the liver, lungs, and intestinal tract. Kaposi sarcoma is characterized by red-purple or blue-brown lesions of the skin, mucous membranes, and other organs. Kaposi sarcoma originates from endothelial cells in response to infection by human herpesvirus type 8 (HHV-8). Immunosuppression (particularly by AIDS and drugs for organ transplant recipients) markedly increases the likelihood of Kaposi sarcoma in HHV-8–infected patients. KS is categorized into the following 4 types: Classic Kaposi sarcoma, AIDS-associated Kaposi sarcoma, Endemic Kaposi sarcoma, and Iatrogenic Kaposi sarcoma. Symptoms depend on specific organ involvement. Mucosal lesions appear as bluish to violaceous macules, plaques, and tumors. GI lesions can bleed, sometimes extensively, but usually are asymptomatic. Diagnosis of Kaposi sarcoma is confirmed by punch biopsy. Surgical excision, cryotherapy, electrocoagulation, intralesional chemotherapy, or possibly topical imiquimod are recommended for superficial lesions and for local radiation therapy and chemotherapy for multiple lesions, diffuse involvement, or lymph node disease.
"Kaposi’s Sarcoma - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Kaposi’s Sarcoma pipeline landscape is provided which includes the disease overview and Kaposi’s Sarcoma treatment guidelines. The assessment part of the report embraces, in depth Kaposi’s Sarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Kaposi’s Sarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Kaposi’s Sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Kaposi’s Sarcoma.
Kaposi’s Sarcoma Emerging Drugs Chapters
This segment of the Kaposi’s Sarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Kaposi’s Sarcoma Emerging Drugs
sEphB4-HAS: Vasgene Therapeutics
sEphB4-HSA, is a recombinant fusion protein, that is being developed by VasGene Therapeutics for the treatment of cancer. sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. In addition, this agent also prevents the angiogenic effects of numerous growth factors due to interactions between Efnb2 and EphB4. The drug is being evaluated in Phase II clinical trial for the treatment of patients with Kaposi’s Sarcoma.
Further product details are provided in the report……..
Kaposi’s Sarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Kaposi’s Sarcoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Kaposi’s Sarcoma
There are approx. 5+ key companies which are developing the therapies for Kaposi’s Sarcoma. The companies which have their Kaposi’s Sarcoma drug candidates in the most advanced stage, i.e. Phase II include, Vasgene Therapeutics.
DelveInsight’s report covers around 5+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Kaposi’s Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Kaposi’s Sarcoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Kaposi’s Sarcoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Kaposi’s Sarcoma drugs.
Kaposi’s Sarcoma Report Insights
- Kaposi’s Sarcoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Kaposi’s Sarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Kaposi’s Sarcoma drugs?
- How many Kaposi’s Sarcoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Kaposi’s Sarcoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Kaposi’s Sarcoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Kaposi’s Sarcoma and their status?
- What are the key designations that have been granted to the emerging drugs?